Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 6
1982 5
1983 2
1984 4
1985 5
1986 10
1987 8
1988 12
1989 11
1990 13
1991 11
1992 16
1993 11
1994 7
1995 16
1996 11
1997 15
1998 14
1999 15
2000 14
2001 26
2002 26
2003 55
2004 52
2005 71
2006 55
2007 73
2008 89
2009 93
2010 80
2011 120
2012 135
2013 158
2014 204
2015 189
2016 202
2017 229
2018 236
2019 278
2020 338
2021 447
2022 483
2023 541
2024 548
2025 727
2026 175

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,227 results

Results by year

Filters applied: . Clear all
Page 1
Pathologic Myopia.
Gu SZ, Chang S. Gu SZ, et al. Adv Exp Med Biol. 2025;1467:281-283. doi: 10.1007/978-3-031-72230-1_54. Adv Exp Med Biol. 2025. PMID: 40736856 Review.
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).
Jin ZC, Wei J, Xiao YD, Si A, Chen JJ, Zhu XL, Li JZ, Nie F, Ding R, Zhou HF, Ding W, Zhong BY, Xie Y, Hu HT, Yin GW, Ji JS, Zhang WH, Shi HB, Wu JB, Xu GH, Yuan CW, Yang WZ, Liu RB, Wu YM, Zheng CS, Xu AB, Huang MS, Li JP, Chen L, Wen SW, Wang YQ, Gu SZ, Li D, Wang D, Zhou GH, Wang WD, Peng Z, Wang X, Zhu HD, Tian J, Teng GJ. Jin ZC, et al. Among authors: gu sz. Hepatology. 2025 Nov 10. doi: 10.1097/HEP.0000000000001593. Online ahead of print. Hepatology. 2025. PMID: 41213031
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.
Shi Y, Han G, Zhou J, Shi X, Jia W, Cheng Y, Jin Y, Hua X, Wen T, Wu J, Gu S, Bai Y, Wang X, Zhang T, Chen Z, Zhang B, Huang M, Liu H, Mao Y, Zhou L, Wang R, Shan Y, Zhang W, Song T, Guo Y, Zhou F, Shao B, Zhang M, Liang B, Zheng J, Zhang G, Shen J, Su W, Zhang F, He Y, Hu S, Liu R, Zhang C, Shen S, Zeng H, Wang TE, Guo W, Shen Y, Chen Y, Li Y, Samol J, Hu H, Zhang W, Du C, Li E, Liu C, Pin CS, Li X, Xu H, Huang JF, Hao C, Lv J, Wang W, Xu Q, Bai A, Zhang X, Liu B, Jin C, Fan J. Shi Y, et al. Among authors: gu s. Lancet Gastroenterol Hepatol. 2025 Jul;10(7):658-670. doi: 10.1016/S2468-1253(25)00059-7. Epub 2025 May 20. Lancet Gastroenterol Hepatol. 2025. PMID: 40409323 Clinical Trial.
Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer.
Nie H, Liao L, Zielinski RJ, Gomez JA, Basi AV, Seeley EH, Tan L, Bilecz AJ, Zhou W, Liu H, Wang C, Wu S, Qi Y, Miyamoto T, Severi F, Goldman AR, Gu S, Sood AK, Jazaeri AA, Drapkin R, Claiborne DT, Zhang N, Lorenzi PL, Burks JK, Lengyel E, Gottlieb E, Zhang R. Nie H, et al. Among authors: gu s. Cancer Res. 2025 Sep 15;85(18):3471-3489. doi: 10.1158/0008-5472.CAN-25-0654. Cancer Res. 2025. PMID: 40658600 Free PMC article.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.
Qin S, Gu S, Chan SL, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Xu L, Yuan X, Li D, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Du J, Shi W, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: gu s. Lancet Oncol. 2025 Dec;26(12):1598-1611. doi: 10.1016/S1470-2045(25)00543-1. Lancet Oncol. 2025. PMID: 41308676 Clinical Trial.
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.
Zhao C, Zhang Y, Wang G, Zheng J, Chen W, Lu Z, Zhuang L, Gu S, Han L, Zheng Z, Yu Z, Yang Y, Sun H, Wei X, Cheng Y, Lin H, Zhu B, Wu G, Lei K, Wang W, Wang Y, Chen K, Xu X, Zheng C, Bi Y, Ding S, Zhang J, Li W, Liu H, Wang J, Liu X, Du Y, Cai L, Wang J, Luo Z, Xing B, Shen J, Yang L, Wu J, Jiang O, Peng Z, Liu X, Cao B, Shen L, Xu A, Li A, Chen S, Fu T, Chen J, Jin C, Zhang L, Lv J, Zhang C, Zhang X, Wang Y, Su H, Zhou Q, Gai W, Xie L, Xu J. Zhao C, et al. Among authors: gu s. Signal Transduct Target Ther. 2025 Aug 6;10(1):249. doi: 10.1038/s41392-025-02333-5. Signal Transduct Target Ther. 2025. PMID: 40769977 Free PMC article. Clinical Trial.
5,227 results